Who
Mark Christopher Bradley
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Alumis.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $136K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 Jun 2024
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $68K2,572 at $26.37 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $68K2,572 at $26.37 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,225 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,225 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —107,100 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —26,750 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,278 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,278 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —130,481 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,481 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —128,342 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —128,342 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,834 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,834 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,093 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,093 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —155,304 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,304 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —53,475 at $0.00 | filing |
News
WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonALMS · dailypolitical.com · 18 Oct 2026Alumis Inc.: Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresALMS · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Mark Christopher Bradley; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.